Inconsistently, in situ hybridization and immunohistochemistry showed that PRL-1 expression was lower in ovarian, breast, and lung cancers and PRL-2 was significantly down-regulated in kidney carcinomas compared to normal tissue (Dumaual et al., 2012). This evidence concerns the gene PTP4A2 and lung cancer.